Fertility preservation in men: a contemporary overview and a look toward emerging technologies

This article discusses the rationale for fertility preservation care in the context of oncologic therapy. It also overviews recent advances in the clinical and basic science realms within oncofertility.

Like Comment
Related Content

VOLUME 115, ISSUE 5, P1126-1139


Robert E. Brannigan, M.D., Richard J. Fantus, M.D., Joshua A. Halpern, M.D., M.S.


Cancer and oncologic therapies can have significant adverse effects on male reproductive potential, leaving many men permanently infertile. Fertility preservation has emerged as a key survivorship issue over the past 20 years, and numerous professional societies have published guidelines calling for fertility preservation to become a routine component of oncologic care. Most males with cancer are able to produce a semen specimen for fertility preservation, but numerous other methods of sperm procurement are available for patients who cannot provide a sufficient sample. Despite these options, fertility preservation will remain a challenge for prepubertal boys and men without sperm production. For these patients, experimental and investigational approaches offer the hope that one day they will translate to the clinical arena, offering additional pathways for successful fertility preservation care.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.